Publications by the researcher in collaboration with RAFAEL VÍCTOR ARROYO GONZÁLEZ (138)

2023

  1. Medical help-seeking intentions among patients with early Alzheimer’s disease

    Frontiers in Psychiatry, Vol. 14

  2. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)

    Revista de neurologia, Vol. 77, Núm. 1, pp. 19-30

  3. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)

    Revista de neurologia, Vol. 77, Núm. 2, pp. 47-60

2022

  1. Awareness of Diagnosis in Persons with Early-Stage Alzheimer’s Disease: An Observational Study in Spain

    Neurology and Therapy, Vol. 11, Núm. 3, pp. 1183-1192

  2. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

  3. Quality of Life and the Experience of Living with Early-Stage Alzheimer's Disease

    Journal of Alzheimer's disease : JAD, Vol. 90, Núm. 2, pp. 719-726

2021

  1. Evolution of antibody titres against Epstein–Barr virus and human herpesvirus 6A/B and expression of multiple sclerosis-associated retrovirus in the serum of pregnant multiple sclerosis patients

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Acetate correlates with disability and immune response in multiple sclerosis

    PeerJ, Vol. 8

2019

  1. Review of the novelties presented at the 2018 ECTRIMS congress: 11th post-ECTRIMS meeting (II)

    Revista de Neurologia, Vol. 68, Núm. 11, pp. 468-479

  2. Review of the novelties presented at the 2018 ectrims congress: 11th post-ectrims meeting (I)

    Revista de Neurologia, Vol. 68, Núm. 10, pp. 431-441

2017

  1. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis

    Multiple Sclerosis, Vol. 23, Núm. 10, pp. 1367-1376

  2. Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: A cross-sectional observational study

    BMJ Open, Vol. 7, Núm. 3

  3. Fingolimod use for the treatment of multiple sclerosis in a clinical practice setting in Madrid

    Clinical Neuropharmacology, Vol. 40, Núm. 1, pp. 29-33

  4. Metabolomic signatures associated with disease severity in multiple sclerosis

    Neurology: Neuroimmunology and NeuroInflammation, Vol. 4, Núm. 2

  5. Multimarker risk stratification approach at multiple sclerosis onset

    Clinical Immunology, Vol. 181, pp. 43-50

  6. Revisión de las novedades del XXXII Congreso ECTRIMS 2016, presentadas en la IX Reunión Post-ECTRIMS (II)

    Revista de Neurologia, Vol. 65, Núm. 2, pp. 75-84

  7. Revisión de las novedades del XXXII congreso ectrims 2016, presentadas en la ix reunión post-ectrims (I)

    Revista de Neurologia, Vol. 65, Núm. 1, pp. 31-40

  8. Sodium intake and multiple sclerosis activity and progression in BENEFIT

    Annals of Neurology, Vol. 82, Núm. 1, pp. 20-29

  9. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort

    European Journal of Clinical Investigation, Vol. 47, Núm. 2, pp. 158-166

2016

  1. A consensus initiative for the assessment of patients newly diagnosed with multiple sclerosis in Spain: the eXamina Project

    Neurodegenerative disease management, Vol. 6, Núm. 5, pp. 363-374